Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:Q06643 (non-Hodgkin's lymphoma)
 11,307 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We investigated the correlations between the in vivo-in vitro induction of 2'-5' oligoadenylate synthetase (2-5A synthetase) by IFN-alpha in cells isolated from patients with low-grade nodular non-Hodgkin's lymphoma (NHL) and subsequent clinical responses of these patients to IFN-alpha therapy. Eleven patients were treated daily with 9 x 10(6) U of IFN-alpha 2a in a phase II trial. After an eight week treatment, four patients achieved complete remission, one a partial response, one a minor response, and five failed to respond. Basal levels of 2-5A synthetase in lymph node tumor B cells and peripheral blood mononuclear cells (PBMC) isolated before therapy differed from patient to patient and were significantly lower than in PBMC from healthy donors (P less than 0.03). In vivo single injections of 9 x 10(6) U IFN-alpha 2a induced the 2-5A synthetase in PBMC from all patients to various degrees without quantitative relation to the clinical responses. Injection of a tenfold lower dose resulted in effects of similar extent in most cases. In vitro, IFN-alpha 2a induced the 2-5A synthetase in lymph node tumor B cells isolated before therapy, and the degree of induction was significantly higher in patients who proved to respond to therapy than in patients who displayed no or minor responses (P less than 0.013). This indicates that, in nodular NHL, the 2-5A synthetase assay may have some predictive value for responsiveness to IFN-alpha therapy.
 ...
PMID:In vivo and in vitro induction of 2'-5' oligoadenylate synthetase by interferon-alpha in nodular non-Hodgkin's lymphoma and correlations with the clinical response. 209 97

Hepatitis C virus (HCV) represents serious threat for human health due to a very high probability for developing chronic liver diseases. The virus has a number peculiarities, which helps him to escape elimination by neutralizing antibodies and immune cells. The main of them are high frequency of the amino acid substitutions within certain immunogenic parts of the viral proteins, the quasispecies nature of the virus, specific functions of the viral proteins, directed against antiviral effects. During acute phase of hepatitis C patients usually have expressed humoral and cellular responses. But only 15% of them have resolved infection. Unfavourable prognostic indications were considered to be high titers of antibodies against NS3 and NS5 proteins, low levels of Th and CTL cell responses, and probably low level of serum 2',5'- oligoadenylate synthetase at the end of acute phase of hepatitis C. Recently it has been shown the existence and significance on E2 protein NOB epitopes, antibodies to which neutralize the virus binding to cells. A lot of CTL- and Th-epitopes were mapped on the viral antigens. Efficiency of humoral and cellular immune response during chronic hepatitis C is limited. Persisting HCV infection may lead to development B-cell lymphoproliferative disorders such a mixed cryoglobulinemia, non-Hodgkin's lymphoma, and to appearence organ-specific and non-organ-specific autoantibodies.
 ...
PMID:Immunity in Different Types of Hepatitis C. 1268 17